MARKET

VRNA

VRNA

Verona Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.55
+0.11
+1.48%
After Hours: 7.55 0 0.00% 16:42 12/04 EST
OPEN
7.28
PREV CLOSE
7.44
HIGH
7.70
LOW
7.11
VOLUME
44.95K
TURNOVER
--
52 WEEK HIGH
15.71
52 WEEK LOW
2.010
MARKET CAP
391.23M
P/E (TTM)
-2.3172
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
25 Best U.S. Cities to Live With Asthma
In this article we take a look at the 25 best U.S. cities to live with asthma. Click to skip ahead and jump to the 10 best U.S. cities to live with asthma. Navigating through life with asthma can be a life-long challenge in itself. Sometimes it becomes very important to constantly monitor your surroundings […]
Insider Monkey · 11/24 19:29
Verona Pharma Secures up to $30 Million Debt Financing from Silicon Valley Bank
Non-dilutive capital to provide further financial flexibilityLONDON and RALEIGH, N.C., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it has entered into a debt financing facility for up to $30 million (“debt facility”) with Silicon Valley Bank (“SVB”). The non-dilutive capital provides further financial flexibility to support pre-commercialization activities for ensifentrine, the Company’s first-in-class product candidate, which is currently in Phase 3 trials. Under the terms of the debt facility, Verona Pharma can borrow up to $30 million in three tranches: $5 million at closing, $10 million available through June 30, 2022 and an additional $15 million available through June 30, 2023. The two latter tranches are contingent upon achievement of certain clinical development milestones and other specified conditions. The loan facility matures on November 1, 2024, with the period prior to December 1, 2023 being interest only.David Zaccardelli, Pharm. D., President and CEO of Verona Pharma, said: “We are pleased to secure this credit facility which provides us with the flexibility to access non-dilutive capital upon achievement of certain clinical development milestones. This will provide additional support, as needed, for pre-commercialization activities for ensifentrine. With this facility and the $200 million raised in July 2020, we believe Verona Pharma has sufficient resources to deliver on our key milestones.”The ENHANCE Phase 3 trials with nebulized ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease (“COPD”) commenced in September 2020. Verona is also conducting a Phase 2 clinical trial to evaluate ensifentrine delivered via pressurized metered-dose inhaler (“pMDI”) formulation in patients with moderate to severe COPD and a pilot study with pMDI ensifentrine in U.S. patients hospitalized with COVID-19.For further information, please contact:Verona Pharma plcTel: +44 (0)20 3283 4200 Victoria Stewart, Director of Communicationsinfo@veronapharma.com    Argot Partners (US Investor Enquiries)Tel: +1 212-600-1902 verona@argotpartners.com Kimberly Minarovich / Michael Barron     Optimum Strategic Communications (European Media and Investor Enquiries)Tel: +44 (0)203 950 9144 verona@optimumcomms.com Mary Clark / Eva Haas / Shabnam Bashir  About Verona PharmaVerona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma’s product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) for COPD maintenance treatment. The Company raised gross proceeds of $200 million through a private placement in July 2020 and expects the funds to support its operations and Phase 3 clinical program into 2023. Two additional formulations of ensifentrine are currently in Phase 2 development for the treatment of COPD: dry powder inhaler (“DPI”) and pressurized metered-dose inhaler (“pMDI”). Ensifentrine is being evaluated in a pilot clinical study in patients hospitalized with COVID-19 and has potential applications in cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.Forward-Looking StatementsThis press release contains forward-looking statements. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from our expectations expressed or implied by the forward-looking statements, including without limitation the important factors discussed under the caption “Risk Factors” in our Registration Statement on Form F-1 filed with the SEC on August 17, 2020, our Report on Form 6-K to be filed with the SEC on November 23, 2020, and our other reports filed with the SEC. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
GlobeNewswire · 11/23 07:00
Verona Pharma Announces November 2020 Virtual Investor Conference Participation
Verona Pharma plc (Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and President, will present a company overview at the following virtual investor conferences in November 2020:
GlobeNewswire · 11/09 07:00
Verona Pharma Plcto Host Earnings Call
NEW YORK, NY / ACCESSWIRE / October 29, 2020 / Verona Pharma Plc (VRNA) (NASDAQ:VRNA) will be discussing their earnings results in their call to be held on 10/29/2020 at 1:00:00 PM Eastern Time.
ACCESSWIRE · 10/29 16:15
Verona Pharma Plcto Host Earnings Call
NEW YORK, NY / ACCESSWIRE / October 29, 2020 / Verona Pharma Plc (VRNA) (NASDAQ:VRNA) will be discussing their earnings results in their call to be held on 10/29/2020 at 1:00:00 PM Eastern Time.
ACCESSWIRE · 10/29 15:16
Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2020
Initiated ENHANCE Phase 3 clinical trials in COPD
GlobeNewswire · 10/29 07:50
Verona Pharma EPS beats by $0.15
Verona Pharma (VRNA): Q3 GAAP EPS of -$0.06 beats by $0.15.Cash and cash equivalents of $185.6M.Press Release
Seekingalpha · 10/29 07:08
Verona Pharma to Announce Interim Results for the Three and Nine Months Ended September 30, 2020 and Provide Corporate Update
Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its unaudited financial results for the three and nine months ended September 30, 2020 on Thursday, October 29, 2020 and host an investment community conference call at 9:00 a.m. EDT / 1:00 p.m. GMT to discuss these financial results and provide a corporate update.
GlobeNewswire · 10/22 06:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VRNA. Analyze the recent business situations of Verona Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VRNA stock price target is 18.80 with a high estimate of 25.00 and a low estimate of 17.00.
EPS
Institutional Holdings
Institutions: 36
Institutional Holdings: 34.96M
% Owned: 67.47%
Shares Outstanding: 51.82M
TypeInstitutionsShares
Increased
8
14.68M
New
20
12.57M
Decreased
3
352.92K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.89%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Non-Executive Chairman
David Ebsworth
Chief Executive Officer/Executive Director
Sven Karlsson
Secretary
Ben Harber
Non-Executive Director
Kenneth Cunningham
Non-Executive Director
Vikas Sinha
Non-Executive Director
Anders Ullman
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About VRNA
Verona Pharma plc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases. The Company is developing ensifentrine, the treatment for respiratory disease. Ensifentrine is an inhaled therapy that acts as both a bronchodilator and an anti-inflammatory agent in one compound. In addition to nebulized ensifentrine, the Company has developed dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI) formulations of ensifentrine for less severe patients. The Company’s subsidiaries include Verona Pharma Inc. and Rhinopharma Limited.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Verona Pharma Plc stock information, including NASDAQ:VRNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VRNA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VRNA stock methods without spending real money on the virtual paper trading platform.